Stephen V Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X about recent paper by H.S. Rugo et al., published in Annals of Oncology:
“Reassuring pooled analysis of 45 patients who had grade 1 pneumonitis from trastuzumab deruxtecan (T-DXd) and were retreated, Annals of Oncology.
Median duration of therapy was 85d, 18% treated for ≥1 year, 33% had reoccurrence of ILD/pneumonitis, all grade 1/2.”
Title: Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Journal: Annals of Oncology
Authors: H.S. Rugo, E. Tokunaga, H. Iwata, V. Petry, E.F. Smit, Y. Goto, D.-W. Kim, K. Shitara, J. Franklin Gruden, S. Modi, J. Cortés, I. Krop, P.A. Jänne, Y. Cheng, C. Taitt, F.-C. Cheng, C.A. Powell
More posts featuring Stephen V Liu on OncoDaily.